•  
  •  
 

Subject Area

Cardiology

Article Type

Original Study

Abstract

Objective The aim was to evaluate early changes of intraocular pressure (IOP) after repeated ranibizumab (Lucentis) injection. Background Ranibizumab is widely used in the treatment of macular edema and choroidal neovascularization. Screening should be frequently done to avoid its adverse effect. Materials and methods A prospective noncomparative case series study was conducted at Menoufia and Kalawoon hospitals, where patients were subjected to intravitreal injection of ranibizumab (Lucentis) for early IOP changes. IOP was measured with a Goldman tonometer before injection, after 30 min, after 1 day, and after 1 week of injection. Results At every time of injection, there was a highly significant difference in IOP measured at 30 min after injection (P < 0.001). However, there was no significant difference measured after 1 day (P = 0.91) and after 1 week of injection (P = 0.56). In repeated intravitreal ranibizumab injection comparison of preoperative, 30 min, 1 day, and 1 week after injection correspondingly, we found no significant difference in IOP measured between first and second injection in preoperative, 30 min, 1 day, and 1 week after injection (P = 0.11, 0.36, 0.17, and 0.26, respectively). However, there was a significant difference in IOP measured between first and third injections regarding preoperative, 30 min, 1 day, and 1 week after injection (P = 0.3, 0.2, 0.1, and 0.3, respectively). Conclusion Ranibizumab injected intravitreally causes a significant transient rise of IOP. The rise is transient for 24 h and normalizes after that.

Download

Share

COinS